Korean J Obstet Gynecol.  2006 May;49(5):1131-1137.

A Clinical Study of 25 Cases of Uterine Papillary Serous Carcinoma

Affiliations
  • 1Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, College of Medicine, Sungkyunkwan University, Seoul, Korea. oncolim.lim@samsung.com
  • 2Department of Obstetrics and Gynecology, Gwangmyoung Cheil Woman's Clinic, Gwangmyoung, Korea.

Abstract


OBJECTIVE
Uterine papillary serous carcinoma (UPSC) has been recognized as an aggressive tumor characterized by deep myometrial invasion and reported high recurrence and low survival rates.
METHODS
We retrospectively investigated the clinicopathologic findings and analyzed the survival rate and prognostic factors in 25 patients with UPSC who were surgically staged at the oncology department between January 1994 and December 2003.
RESULTS
The mean age of the cases was 55.8 (range: 45-69) years. The most frequent presenting symptom was abnormal uterine bleeding (88%). According to FIGO staging, seven of the cases were stage I, six of the cases were stage II, eleven of the cases were stage III, and one case was stage IV. Mean follow up period is 42.7 months (range: 9-123 months). Overall survival rate was 80 percent. The recurrence was seen in 5 patients (25%).
CONCLUSION
Univariate analysis showed that invasion of uterine serosa, ovarian and tubal metastasis, and positive peritoneal washing cytology were significantly associated with prediction of prognosis. In multivariate analysis, tubal metastasis was an independent prognostic factor for overall survival.

Keyword

Uterine papillary serous carcinoma (UPSC); Prognostic factor; Survival rate

MeSH Terms

Follow-Up Studies
Humans
Multivariate Analysis
Neoplasm Metastasis
Prognosis
Recurrence
Retrospective Studies
Serous Membrane
Survival Rate
Uterine Hemorrhage
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr